Monitor for future ATM sales announcements, which will signal immediate dilution and potential downward pressure on the stock price. The resale filing increases the potential supply of shares in the market, which could weigh on the stock, especially if selling stockholders are active. The termination of the Jefferies agreement and switch to TD Securities is a routine administrative change.
Price Chart
Executive Summary
Kymera Therapeutics entered into a $500 million at-the-market (ATM) equity offering agreement with TD Securities (USA) LLC, terminated its prior ATM agreement with Jefferies LLC, and filed a resale prospectus supplement for up to 31.4 million shares held by certain selling stockholders. The ATM program allows Kymera to raise capital opportunistically, while the resale filing enables passive selling by existing investors without Kymera receiving proceeds.
Key Financial Metrics
Key Facts
- Entered into a $500 million at-the-market (ATM) equity offering agreement with TD Securities (USA) LLC.
- Terminated the prior Open Market Sale Agreement with Jefferies LLC.
- Filed a resale prospectus supplement for up to 18.8 million common shares and 12.6 million warrant shares held by selling stockholders.
- The ATM program allows Kymera to sell shares from time to time at its discretion, with TD Securities acting as sales agent for a commission of up to 3.0%.
- Kymera will not receive any proceeds from the resale of shares by the selling stockholders.
Financial Impact
Up to $500 million in potential gross proceeds for Kymera from the ATM offering; no proceeds to Kymera from the resale of up to 31.4 million shares by selling stockholders.
Risk Factors
- Dilution from future ATM sales could pressure the stock price.
- Increased share supply from the resale of up to 31.4 million shares by selling stockholders could create downward pressure on the stock price.
- Market perception of the ATM program as a sign of near-term funding needs could be negative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073561 |
| Document: d114045d8k.htm | 0001193125-26-073561 |
| Document: d114045dex51.htm | 0001193125-26-073561 |
| Document: d114045dex52.htm | 0001193125-26-073561 |
| Document: 0001193125-26-073561-index-headers.html | 0001193125-26-073561 |
| Document: 0001193125-26-073561-index.html | 0001193125-26-073561 |
| Document: 0001193125-26-073561.txt | 0001193125-26-073561 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 14w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access